Fall Clinical Dermatology Conference 2026: Lilly, J&J, Arcutis, Alumis, Sagimet Stocks Jump on New Data

Key Highlights

• Five healthcare stocks moved Friday after companies shared new psoriasis and acne trial results at a major dermatology conference in Las Vegas.
• Arcutis Biotherapeutics led gainers after presenting infant-focused skin trial data, while Sagimet Biosciences shared long-term acne study results from its Phase 3 program.
• Alumis and Johnson & Johnson both showed strong, long-lasting skin clearance data from separate oral psoriasis drug programs still in development.
• Eli Lilly's combination data linked psoriasis treatment with weight-loss drug Zepbound, pointing to a possible immune and metabolic health connection.

Dermatology stocks had a busy week. The Fall Clinical Dermatology Conference 2026 in Las Vegas became the stage for a wave of new trial results, and investors took notice. From acne to psoriasis, five companies shared data that could shape how these common skin conditions are treated in the years ahead. Here is a simple breakdown of what each company announced and how their stock reacted.

Sagimet Biosciences (NASDAQ:SGMT): Acne Pill Holds Up Through a Full Year of Data

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing oral treatments for diseases linked to fatty acid overproduction, including acne and liver disease. The company shared 52-week results from a Phase 3 extension study of denifanstat, an oral pill being developed for moderate to severe acne. The data, generated by license partner Ascletis in China, showed continued improvement in skin clearance through a full year of treatment, with the drug generally well tolerated. Sagimet is also moving forward with its own U.S. Phase 3 trial, called AURORA, which has started screening patients. Shares traded around USD 8.90, down 0.28% on the day even as the company highlighted encouraging long-term numbers.

Eli Lilly and Company (NYSE:LLY): A New Link Between Psoriasis and Weight Loss Drugs

Eli Lilly is a global pharmaceutical company known for its diabetes, obesity, and immunology treatments, including Zepbound and Taltz. Lilly presented new data exploring what happens when its psoriasis drug Taltz is combined with weight-loss treatment Zepbound in patients who have both psoriasis and obesity. The analysis found broader changes in biological markers linked to both conditions when the two drugs were used together compared to Taltz alone. This may support the idea that psoriasis and obesity are connected on a deeper, biological level. Lilly shares traded near USD 1,178.04, up 0.72% on the day as investors digested the data alongside other company news.

Alumis (NASDAQ:ALMS): Scalp and Itch Relief Data Impresses the Market

Alumis is a late-stage biopharmaceutical company developing oral treatments that target immune-mediated diseases such as psoriasis and lupus. The company offered a strong update on envudeucitinib, its oral psoriasis pill still in late-stage testing. New data showed more than 80% of patients kept clear or almost clear scalp skin after 48 weeks, along with fast and lasting relief from itching. The company said it remains on track to file for FDA approval in the fourth quarter of 2026. Alumis shares moved higher, up 1.65% and trading around USD 7.09 as the market responded positively to the durability of the results.

Johnson & Johnson (NYSE:JNJ): Two Years of Clear Skin Data Stands Out

Johnson & Johnson is a diversified global healthcare company spanning pharmaceuticals and medical technology. The company shared two-year data for ICOTYDE, its oral psoriasis pill that works differently from injectable treatments. The results showed that most patients kept clear or nearly clear skin all the way through week 112, with no new safety concerns reported. For a disease that often requires lifelong management, this kind of long-term consistency stood out to doctors and investors alike. J&J shares traded near USD 260.76, up 1.67% and continuing a steady climb ahead of upcoming earnings.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): The Biggest Mover of the Week

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on treatments for immune-mediated skin diseases. The company was the standout mover of the group this week. It presented new data on ZORYVE, its roflumilast cream, including results from a trial in infants as young as three months old. The study showed rapid improvement in skin symptoms with no serious side effects reported among participants. Combined with continued strong prescription growth, the news sent Arcutis shares up sharply, climbing 8.72% to trade near USD 26.63, marking one of the biggest single-day gains among dermatology stocks this week.

Where Things Stand

The Fall Clinical Dermatology Conference has turned into more than just a medical event. For investors tracking healthcare stocks, it has become a real catalyst, with five separate companies moving on new data in the same week. Psoriasis and acne may not sound like high-stakes medical conditions, but they affect millions of people and represent a market where even small improvements in treatment can shift sentiment quickly. As these programs move closer to regulatory decisions, this group of stocks may continue to see data-driven swings in the months ahead.